Table 1.

Characteristics of study population (n = 18,454)a

CharacteristicValue
Patient demographics
    race (%)
        white69.4
        black25.3
        other/unknown5.3
    age (yr; mean)75.7
    male gender (%)51.2
Facility characteristics
    region (%)
        Northeast (networks 1 to 5)24.0
        Southeast (networks 6 to 8, 13, 14)35.4
        Midwest (networks 9 to 12)23.9
        West (networks 15 to 18)16.6
    chain membership (%)
        chain 130.6
        chain 214.1
        chain 315.1
        chain 48.8
        chain 53.8
        chain 62.2
    small chain/nonchain25.4
Patient clinical history (%)
    cause of ESRD
        diabetes46.9
        hypertension36.1
        glomerulonephritis5.1
        cystic kidney1.0
        other10.9
    body weight (kg)
        <6123.9
        61 to <7225.7
        72 to 8424.3
        ≥8426.2
    Charlson index scoreb
        <318.2
        3 to <629.4
        6 to <821.0
        ≥831.4
    baseline hospitalization (d)b
        056.1
        <511.4
        5 to <1012.8
        ≥1019.7
    cardiovascular comorbidities (% yes)63.1
    noncardiovascular comorbidities (% yes)61.4
Anemia management practices
    receipt of predialysis epoetin (% yes)35.1
    hematocrit level at end of month 3 (%)
        <306.5
        30 to <3310.5
        33 to <3620.1
        36 to <3927.6
        ≥3935.3
    epoetin dosage administered (U/wk)b
        <10,0009.8
        10,000 to <20,00034.5
        20,000 to <30,00030.5
        30,000 to <40,00014.5
        ≥40,00010.6
    Average iron administered (mg/mo)b
        <45020.2
        450 to <80019.4
        800 to <120024.6
        ≥120035.8
  • a All variables in Table 1 were adjusted for in the survival analyses. Unless otherwise noted, all variables were collected at study entry.

  • b First 3 mo of dialysis therapy.